Program
Estradiol
Also written as “NOMAC-E2”, “estradiol, 25 mcg” and “estradiol, 10 mcg”.
Its studies are mostly in Hot Flashes · Dyspareunia · Atrophic Vaginitis · Leiomyoma · Menorrhagia, led by 21 companies.
Drug pageEstradiol: every studyMany companies study it; this page follows only the 55 they lead. All 300 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordiskits history only | 120 open or running | phase 4since Oct 8, 2012 | Apr 19, 2005 | none ahead |
| Bayerits history only | 100 open or running | phase 4since Sep 12, 2005 | Sep 9, 2005 | none ahead |
| AbbVieits history only | 80 open or running | phase 3since Feb 17, 2010 | Feb 17, 2010 | none ahead |
| Teva Pharmaceutical Industriesits history only | 30 open or running | phase 3since Nov 7, 2022 | Jul 2, 2010 | none ahead |
| TherapeuticsMDits history only | 30 open or running | phase 3since Sep 5, 2013 | Sep 5, 2013 | none ahead |
| Grünenthalits history only | 20 open or running | phase 1since Nov 9, 2018 | Nov 9, 2018 | none ahead |
| Merckits history only | 20 open or running | phase 1since Nov 26, 2008 | Nov 26, 2008 | none ahead |
| Renovoits history only | 20 open or running | phase 3since Jan 24, 2007 | Jan 24, 2007 | none ahead |
| Amneal Pharmaceuticalsits history only | 10 open or running | phase 3since Jan 28, 2013 | Jan 28, 2013 | none ahead |
| ASCEND Therapeuticsits history only | 10 open or running | phase 4since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| BioSante Pharmaceuticalsits history only | 10 open or running | phase 3since Oct 20, 2006 | Oct 20, 2006 | none ahead |
| Centro A.F. de Estudios Tecnologicosits history only | 10 open or running | phase 3since Oct 16, 2008 | Oct 16, 2008 | none ahead |
| Corium Innovationsits history only | 11 open or running | phase 1since Aug 26, 2026 | Aug 26, 2026 | May 31, 2027phase 1 · NCT07794150 |
| Hamad Medicalits history only | 10 open or running | phase 2since Apr 6, 2021 | Apr 6, 2021 | none ahead |
| Lotus Pharmaceuticalits history only | 10 open or running | phase 3since Dec 14, 2016 | Dec 14, 2016 | none ahead |
| Padagisits history only | 10 open or running | phase 3since May 10, 2016 | May 10, 2016 | none ahead |
| Prascoits history only | 10 open or running | phase 3since Nov 1, 2017 | Nov 1, 2017 | none ahead |
| Productos Científicos S. A. de C. V.its history only | 10 open or running | phase 1since Feb 10, 2011 | Feb 10, 2011 | none ahead |
| Sun Pharmaceutical Industriesits history only | 10 open or running | phase 3since Dec 15, 2012 | Dec 15, 2012 | none ahead |
| Upsher-Smith Laboratoriesits history only | 10 open or running | phase 3since Jul 29, 2008 | Jul 29, 2008 | none ahead |
| Viramalits history only | 10 open or running | phase 1since Jun 1, 2018 | Jun 1, 2018 | none ahead |
Also a collaborator on its studies: IQVIA Pty, Abbott, Simbec Research, Laboratoires Besins International and Grünenthal.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 41 studies since Apr 19, 2005.
- May 18, 2015Phase 2 study in DyspareuniaTherapeuticsMD · NCT02449902 · 50 enrolled · United States
- Jan 8, 2016Phase 3 study in LeiomyomaAbbVie · NCT02654054 · 413 enrolled · United States, Canada, Puerto Rico
- Feb 22, 2016Phase 3 study in LeiomyomaAbbVie · NCT02691494 · 378 enrolled · United States, Canada
- May 10, 2016Padagis’s first study: phase 3 study in AtrophyNew to PadagisPadagis · NCT02770365 · 695 enrolled · United States
- Dec 14, 2016Lotus Pharmaceutical’s first study: phase 3 study in Atrophic VaginitisNew to Lotus PharmaceuticalLotus Pharmaceutical · NCT02995694 · 535 enrolled
- Jul 7, 2017Phase 3 study in EndometriosisAbbVie · NCT03213457 · 681 enrolled · United States, Canada, Puerto Rico
- Aug 31, 2017Phase 3 study in MenorrhagiaAbbVie · NCT03271489 · 478 enrolled · United States, Puerto Rico
- Nov 1, 2017Prasco’s first study: phase 3 study in PruritusNew to PrascoPrasco · NCT03332303 · 540 enrolled · United States
- Jun 1, 2018Viramal’s first study: phase 1 study in MenopauseNew to ViramalViramal · NCT03556800 · 20 enrolled · United Kingdom
- Nov 9, 2018Grünenthal’s first study: phase 1 study in BioequivalenceNew to GrünenthalGrünenthal · NCT03749733 · Mexico
- Apr 6, 2021Hamad Medical’s first study: phase 2 study in COVID-19New to Hamad MedicalHamad Medical · NCT04853069 · 2,000 enrolled · Qatar
- Apr 5, 2022Phase 1 study in BioequivalenceGrünenthal · NCT05332106 · 10 enrolled · India
- Nov 7, 2022Phase 3 study in DyspareuniaTeva Pharmaceutical Industries · NCT05617820 · 1,050 enrolled · United States, El Salvador, Honduras
- Aug 26, 2026Corium Innovations’ first study: phase 1 study in MenopauseNew to Corium InnovationsCorium Innovations · NCT07794150 · 250 planned · United States, India
Ahead
- May 31, 2027Primary completion: phase 1 study in MenopauseCorium Innovations · NCT07794150
TargetBeta
“Estrogen receptor alpha agonist”ChEMBL 37, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 55 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07794150Menopause · United States, India | 1 | Recruiting | Corium Innovations | May 31, 2027 | 250 |
| NCT05617820Dyspareunia · United States, El Salvador, Honduras | 3 | Completed | Teva Pharmaceutical Industries | Mar 15, 2024 | 1,050 |
| NCT05332106Bioequivalence · India | 1 | Completed | Grünenthal | Mar 22, 2022 | 10 |
| NCT04853069COVID-19 · Qatar | 2 | UNKNOWN | Hamad Medical | Feb 28, 2022 | 2,000 |
| NCT03749733Bioequivalence · Mexico | 1 | Withdrawn | Grünenthal | Dec 2019 | 0 |
| NCT03556800Menopause · United Kingdom | 1 | UNKNOWN | Viramal | Jun 30, 2022 | 20 |
| NCT03332303Pruritus · United States | 3 | Completed | Prasco | Mar 15, 2018 | 540 |
| NCT03271489Menorrhagia · United States, Puerto Rico | 3 | Completed | AbbVie | Jun 28, 2024 | 478 |
| NCT03213457Endometriosis · United States, Canada, Puerto Rico | 3 | Completed | AbbVie | Mar 27, 2020 | 681 |
| NCT02995694Atrophic Vaginitis | 3 | Completed | Lotus Pharmaceutical | Dec 2016 | 535 |
| NCT02770365Atrophy · United States | 3 | Completed | Padagis | Nov 2016 | 695 |
| NCT02691494Leiomyoma · United States, Canada | 3 | Completed | AbbVie | Feb 14, 2018 | 378 |
| NCT02654054Leiomyoma · United States, Canada, Puerto Rico | 3 | Completed | AbbVie | Jan 18, 2018 | 413 |
| NCT02449902Dyspareunia · United States | 2 | Completed | TherapeuticsMD | Sep 2013 | 50 |
| NCT02253173Dyspareunia · United States, Canada | 3 | Completed | TherapeuticsMD | Oct 2015 | 764 |
| NCT01942668Hot Flashes · United States | 3 | Completed | TherapeuticsMD | Oct 28, 2016 | 1,845 |
| NCT01845649Dyspareunia · United States | 3 | Completed | AbbVie | Nov 20, 2013 | 550 |
| NCT01779947Atrophic Vaginitis Due to Menopause · United States | 3 | Completed | Amneal Pharmaceuticals | Sep 2012 | 519 |
| NCT01753102Vulvar Atrophy · India | 3 | Terminated | Sun Pharmaceutical Industries | Apr 30, 2013 | 49 |
| NCT01710696Genetic Diseases, Inborn · Spain | 3 | Completed | Novo Nordisk | Jul 26, 2004 | 50 |
| NCT01705249Menopause · Norway, Sweden | 4 | Completed | Novo Nordisk | Jun 6, 2003 | 191 |
| NCT01638910Contraception · China, Hong Kong, India and more | 3 | Completed | Bayer | Nov 2014 | 955 |
| NCT01596010Menopause · Germany | 1 | Completed | Novo Nordisk | Nov 2007 | 44 |
| NCT01486979Menopause · Germany | 1 | Completed | Novo Nordisk | May 2007 | 58 |
| NCT01477632Menopause · Germany | 1 | Completed | Novo Nordisk | Jun 2005 | 24 |
| NCT01455597Vulvovaginal Atrophy · United States | 3 | Completed | AbbVie | Dec 3, 2012 | 309 |
| NCT01400776Postmenopausal Vulvovaginal Atrophy · United States | 3 | Completed | AbbVie | Feb 27, 2012 | 722 |
| NCT01293747Menopause · Mexico | 1 | Completed | Productos Científicos S. A. de C. V. | Aug 2011 | 30 |
| NCT01181726Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Feb 2007 | 40 |
| NCT01157182Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Apr 2007 | 36 |
| NCT01085877Menopause · Germany | 1 | Completed | Novo Nordisk | May 2010 | 70 |
| NCT01070979Hormone Replacement Therapy · United States | 3 | Completed | AbbVie | Sep 2003 | 249 |
| NCT00984386Cicatrix · United Kingdom | 2 | Completed | Renovo | Apr 2005 | 44 |
| NCT00909857Primary Dysmenorrhea · United States, Canada, Chile and more | 3 | Completed | Bayer | Nov 2010 | 507 |
| NCT00820664Postmenopausal Symptoms | 1 | Completed | Merck | May 2009 | 29 |
| NCT00799708Postmenopause | 1 | Completed | Merck | Oct 2008 | 27 |
| NCT00775242Hot Flashes · Mexico | 3 | Completed | Centro A.F. de Estudios Tecnologicos | Nov 2008 | 103 |
| NCT00754065Contraception · United States, Canada | 3 | Completed | Bayer | May 10, 2011 | 409 |
| NCT00727129Hot Flashes | 3 | Completed | Upsher-Smith Laboratories | 495 | |
| NCT00560924Menopause · Sweden | 3 | Terminated | Novo Nordisk | Mar 17, 2004 | 6 |
| NCT00522873Hot Flashes · United States, Argentina, Austria and more | 3 | Completed | Bayer | Aug 2009 | 662 |
| NCT00465192Menopause | 3 | Completed | Novo Nordisk | Nov 30, 1995 | 230 |
| NCT00464971Menopause | 3 | Completed | Novo Nordisk | Nov 30, 1996 | 102 |
| NCT00446199Hot Flashes · United States | 3 | Completed | Bayer | Oct 2008 | 735 |
| NCT00431132Menopause · Czech Republic, Denmark, Finland and more | 3 | Completed | Novo Nordisk | Nov 2008 | 336 |
| NCT00426972Burns · Germany, Latvia, Russian Federation and more | 3 | Completed | Renovo | Jul 2008 | 148 |
| NCT00391417Hot Flashes | 3 | Completed | BioSante Pharmaceuticals | 431 | |
| NCT00356447Vasomotor Symptoms · China | 3 | Completed | Bayer | Oct 2007 | 249 |
| NCT00310531Bone Diseases, Metabolic | 3 | Completed | Bayer | 500 | |
| NCT00184795Hot Flashes · Austria, Belgium, Denmark and more | 3 | Completed | Novo Nordisk | May 4, 2005 | 576 |
| NCT00206622Hot Flashes · United States | 4 | Completed | Bayer | 425 | |
| NCT00185328Postmenopause | 4 | Completed | Bayer | 55 | |
| NCT00185237Hot Flashes | 3 | Completed | Bayer | Nov 2006 | 165 |
| NCT00160173Postmenopausal Symptoms · United States | 4 | Completed | ASCEND Therapeutics | Sep 6, 2005 | 221 |
| NCT00108849Menopause · United States, Canada | 3 | Completed | Novo Nordisk | May 2007 | 309 |
How it is read
Names in the registry
- “Estradiol”, 7 entries
- “NOMAC-E2”, 6 entries
- “estradiol, 25 mcg”, 5 entries
- “estradiol, 10 mcg”, 4 entries
- “Zesteem”, 4 entries
Conditions, from the studies’ own filings
- Hot Flashes, 9 studies
- Dyspareunia, 4 studies
- Atrophic Vaginitis, 2 studies
- Leiomyoma, 2 studies
- Menorrhagia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.